academic article

• Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial..  Lancet neurology.  19:988-997. 2020
• Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis..  The New England journal of medicine.  376:221-234. 2017
• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis..  The New England journal of medicine.  376:209-220. 2017
• Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial..  Annals of neurology.  61:14-24. 2007